PR
News
notice
Xcell Therapeutics to launch dedicated exosome & NK media later this year
2023.02.24
Xcell Therapeutics to launch dedicated exosome & NK media later this year
Xcell Therapeutics, a leading domestic media company, will launch exosome-specific media and natural killer cell (NK) specific media this year. It is expanding its core pipeline.
According to Xcell Therapeutics on Thursday, the new products will be launched in April for exosome-specific media and in the second half of the year for NK-specific media.
"The exosome badge will be introduced for the first time through a seminar attended by global authorities and relevant people," said a company official.
Global market research firm DataBridge Market Research (DBMR) forecasts the global exosome-related market to grow from $11.74 billion in 2021 to $36.92 billion in 2026, at a CAGR of 21.9%.
The NK cell therapy market, which is the second most researched after T cell therapy, is also considered a promising market. The market size is expected to grow from 1.4 billion won ($1.8 trillion) in 2018 to 5.6 billion won ($7.2 trillion) in 2026, according to a report by Invest Securities.
Currently, Xcell Therapeutics has launched a dedicated medium for mesenchymal stem cells (MSCs) and a dedicated medium for dermal placental cells (DPCs). Xcell Therapeutics is the first company in the world to develop a chemically formulated serum-free medium for stem cells that is cGMP-grade.
After being recognized for its technology both domestically and overseas, the company built and operates a cGMP-grade production plant in Yongin. The Yongin plant has an annual production capacity of 100,000 liters.
In 2020, the company introduced a VTM automation device and established a large-scale mass production system. In May 2021, its flagship product, Serum-free Chemically Defined Media, became the first new product (NEP) certified in Korea.
In December last year, it was named as a world-class product organized by the Ministry of Trade, Industry and Energy and selected by KOTRA (Korea Trade-Investment Promotion Agency).
NEP certification is a government quality certification system for innovative products that have been in commercialization for less than three years that are the first new technology products developed in Korea. This certification is the most difficult to obtain among the quality-related certifications issued by the government.
Adding exosome and NK-specific media to the pipeline is expected to expand the company's position as an industrial specialized media company.
Xcell Therapeutics has also secured its own highly efficient customized media development platform technology (CAMP). "With CAMP, we can quickly build a pipeline," said Lee, "and we plan to continue to launch specialized media for advanced bio in various fields."